SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) — Adaptive Research, an integrated clinical trial site organization with the unique purpose of democratizing clinical trials by integrating local physicians into the clinical trial process, announced today , Perminder Bhatia, MD, was appointed Chief of Neurology reporting to the Chief Medical Officer.
“2022 has been an incredible year of growth for Adaptive Research.With our continued expansion, we are thrilled to have Perminder join our team. Combined with his ability to conduct clinical trials, he is an ideal candidate to lead our Neurology Division.Dr. Existing scientific and medical expertise in the field will be enhanced.Looking ahead this year, we plan to add expertise in other therapeutic areas, including oncology, and expand our footprint across multiple geographic areas. I look forward to it.”
Perminder Bhatia, Ph.D., is a board-certified neurologist, principal investigator and director of clinical trials at Neuropain Medical Center, founded in Fresno, CA in 2003. Center where he was previously the Chief of Neurology. Previously, Dr. Bhatia was Deputy Chief of Medicine at Rideout Memorial Hospital. Since 2003, Dr. Bhatia has completed over 100 of his clinical trials and published numerous research papers. He completed his MBBS in Punjab, India and Albert He earned his M.D. from Einstein College of Medicine. He completed his Neurology Specialization at the State University of New York at Buffalo.
“At Neuropain Medical Center, we pride ourselves on compassionate care by providing patients with access to clinical trials that may improve their condition. The team at Adaptive Research is passionate about the same ideals. “We are very excited to expand our ability to bring clinical trials to community clinics to enhance patient care,” concluded Dr. Bhatia.
About Adaptive Research
Adaptive Research is an integrated clinical trial site organization with the unique purpose of democratizing clinical trials by leveraging digital technology and integrating local physicians and relevant regional networks into the clinical trial process. By introducing new community clinics into clinical trials, Adaptive enables life sciences companies to tap into larger, undiluted, and more diverse patient pools to accelerate drug/device development. Adaptive aims to ensure patient diversity, increase patient access to potentially life-saving investigational drugs, devices, or innovative disruptive technologies, and achieve improved clinical trial outcomes. We provide a wide range of solutions for technology/pharmaceutical sponsors, contract research organizations and clinical trial sites. For additional information, please visit https://adaptiveresearch.com.
Matt de Luna